SCHEMBL170541

SCHEMBL170541

c1ccc([C]2CCCCC2c2ccccc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 1/20 0.41
ALOX15 P16050 1/20 0.41
NOS1 P29475 2/20 0.41
NOS2 P35228 2/20 0.41
DDB1 Q16531 1/20 0.38
CRBN Q96SW2 1/20 0.38
CFTR P13569 1/20 0.38
GOPC Q9HD26 1/20 0.38
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
TP53 P04637 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
SLC18A3 Q16572 1/20 0.36
HRH4 Q9H3N8 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
PDGFRA P16234 1/20 0.35
PRKACA P17612 1/20 0.35
KDR P35968 1/20 0.35
CDK8 P49336 1/20 0.35
CDK9 P50750 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15758247 0.94 IGF1R (0.46) IGF1RALOX15DDB1CRBNCFTR
SCHEMBL14880674 0.85 DDB1 (0.46) IGF1RALOX15DDB1CRBNCFTR
SCHEMBL11482777 0.77 ESR2 (0.39)
SCHEMBL28835484 0.76 IGF1R (0.38) IGF1RALOX15NOS1NOS2DDB1
SCHEMBL7700085 0.75 CHRNB4 (0.41) NOS1NOS2ALDH1A1CHRNB4CHRNA3
SCHEMBL5534036 0.75 HRH2 (0.41) NOS1NOS2ALDH1A1GAAL3MBTL1
SCHEMBL28512805 0.74 IGF1R (0.37) IGF1RALOX15NOS1NOS2DDB1
SCHEMBL15874652 0.73 SLC18A3 (0.51) IGF1RALOX15NOS1NOS2DDB1
SCHEMBL6367893 0.73 CHRNB4 (0.35) NOS1NOS2ALDH1A1SLC18A3CHRNB4
SCHEMBL4105567 0.73 IGF1R (0.42) IGF1RALOX15NOS1NOS2DDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104081416-A Methods and compositions for objectively characterizing medical images ANNAPRAGADA ANANTH 2014-10-01 CN claimed
US-8409468-B2 Liquid crystal composition, liquid crystal panel using the same, and liquid crystal shutter glasses KABUSHIKI KAISHA TOSHIBA (JP) 2013-04-02 US claimed
US-20100125154-A1 PHOSPHORUS COMPOUND AND METHOD FOR PREPARING THE SAME CHANG CHUN PLASTIC CO., LTD. (TW) 2010-05-20 US claimed
EP-2186816-A1 Phosphorus compound and method for preparing the same Chang Chun Plastics Co., Ltd. (TW) 2010-05-19 EP claimed
EP-1654225-A4 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AMGEN INC (US) 2007-11-28 EP claimed
EP-1654225-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS Amgen, Inc. (US) 2006-05-10 EP claimed
US-20050256161-A1 Melanin concentrating hormone receptor antagonists AMGEN INC. 2005-11-17 US claimed
WO-2005019240-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AMGEN, INC. (US) 2005-03-03 WO claimed
EP-0216672-B1 MIXTURE OF NEMATIC LIQUID CRYSTALS CONTAINING A 1-(ALKYL CYCLOHEXYL)-2-(ALKYL FLUORO BISPHENYLYL) ETHANE COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 1991-01-16 EP claimed
EP-0032397-A1 Method of manufacturing a liquid crystal display SIEMENS AKTIENGESELLSCHAFT (DE) 1981-07-22 EP claimed
CN-118302713-A Laminated glass and liquid crystal device 大日本印刷株式会社 2024-07-05 CN disclosed
US-12019337-B2 Laminated glass and production method for laminated glass DAI NIPPON PRINTING CO., LTD. (JP) 2024-06-25 US disclosed
US-20240059049-A1 LIGHT MODULATING DEVICE, MANUFACTURING METHOD THEREFOR, AND LIQUID CRYSTAL DEVICE DAI NIPPON PRINTING CO., LTD. (JP) 2024-02-22 US disclosed
WO-2024034687-A1 LIGHT CONTROL MEMBER, METHOD FOR PRODUCING LIGHT CONTROL MEMBER, AND LIGHT CONTROL BODY 大日本印刷株式会社 2024-02-15 WO disclosed
WO-2023248380-A1 HEAT CONDUCTIVE RESIN COMPOSITION, HEAT CONDUCTIVE SHEET AND METHOD FOR MANUFACTURING SAME, HEAT CONDUCTIVE CURED PRODUCT AND METHOD FOR MANUFACTURING SAME, POWER MODULE, AND STATOR OF MOTOR 三菱電機株式会社 2023-12-28 WO disclosed
US-4795788-A RUTHENIUM COMPLEX BAYER AKTIENGESELLSCHAFT (DE) 1989-01-03 US disclosed
US-4746707-A DIENE-NITRILE COPOLYMERS USING A RUTHENIUM COMPLEX CATALYST BAYER AKTIENGESELLSCHAFT (DE) 1988-05-24 US disclosed
EP-0255956-A2 P-Type liquid crystal composition Sato, Hisato (JP) 1988-02-17 EP disclosed
US-4370028-A Method of producing liquid crystal display devices with alignment layer formed from organic tin compound of the type Rn SnX4-n SIEMENS AKTIENGESELLSCHAFT (DE) 1983-01-25 US disclosed
US-4239704-A FROM METHANOL, CARBON MONOXIDE, AND HYDROGEN GULF RESEARCH & DEVELOPMENT COMPANY (US) 1980-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100125154-A1 PHOSPHORUS COMPOUND AND METHOD FOR PREPARING THE SAME PHOSPHO1, PFAS, PPA1 IGF1R 3403/4885ALOX15 673/4885NOS1 4420/4885
US-20050256161-A1 Melanin concentrating hormone receptor antagonists MCHR1, MC1R, NPY1R IGF1R 433/4885ALOX15 2129/4885NOS1 3094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.